Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Leukoplakia, Oral Benign Neoplasms For this study an Oral Premalignant Lesions (OPL) is defined as a lesion which can atypical hyperplasia, atypical hyperkeratosis, leukoplakia, and erythroplakia/erythro-leukoplakia. Histology MUST be confirmed by an MSKCC pathologist for all participating sites. An OPL may be located in the oral cavity, oropharynx The subj has a histologically suspected or confirmed index oral premalignant lesion, 12mm or greater in size that has not been bx'd in the past 6 wks. Each index lesion must be either An EARLY premalignant lesion defined to be at high risk as indicated by the presence of at least one of the following: atypical cells or mild dysplasia, or hyperplastic leukoplakia of high-risk sites, lateral and ventral tongue and floor or mouth OR An premalignant lesion defined as the presence of at least one of the following: moderate dysplasia or severe dysplasia (excluding CIS) The subj is > 18 yrs of age The subj's life expectancy is > 12 wks and Zubrod performance status is 0 or 1 (Appendix VIII) The subj meets the following lab during a time not to exceed 4 wks prior to randomization Hemoglobin level above 10g/dL for women and above 12g/dL for men WBC count > 3,000 uL Platelets count > 125,000 uL  The subject has had chemotherapy, immunotherapy, hormonal tx (other than HRT for menopause), or RT within 3 wks of the Baseline visit The subj has not recovered from the acute toxic effects of chemotherapy, immunotherapy, hormonal tx, or RT The subj will need concurrent chemotherapy, radiotherapy, hormonal (other than HRT for menopause), or immunotherapy during the time of study The subj has a history of hypersensitivity to sulindac, COX-2 inhibitors, NSAIDs, salicylates The subj has been diagnosed with or has been treated for esophageal, gastric, pyloric channel, or duodenal ulceration The subj has a history of inv cancer within the past 1 yr (excluding non-melanoma skin cancer and in situ cervical cancer) The subj has a chronic or acute renal or hepatic disorder or a significant bleeding disorder or any other condition which, in the Institutional Principal Investigator's opinion, might preclude study participation The subj has a past history of or active inflammatory bowel disease (eg. Crohn's disease or ulcerative colitis) or pancreatic disease The subj has received any investigational medication within 30 ds of the Baseline visit or is scheduled to receive an investigational drug during the course of the study The subj is, in the opinion of the Institutional Principal Investigator, not an appropriate candidate for study participation